Article Text

PDF
P151 Tiotropium Respimat® add-on therapy reduces exacerbation risk in patients with moderate or severe symptomatic asthma, independent of TH2 status
  1. T Casale1,
  2. R Dahl2,
  3. JC Virchow3,
  4. M Engel4,
  5. P Moroni-Zentgraf4,
  6. R Lühmann5,
  7. HAM Kerstjens6
  1. 1Division of Allergy and Immunology, University of South Florida Morsani College of Medicine, Tampa, Florida, USA
  2. 2Odense University Hospital, Odense, Denmark
  3. 3Department of Pneumology, Intensive Care Medicine, Zentrum Für Innere Medizin, Klinik I, University Clinic Rostock, Rostock, Germany
  4. 4TA Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim Am Rhein, Germany
  5. 5Global Biometrics and Clinical Applications, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an Der Riss, Germany
  6. 6University of Groningen, Department of Pulmonary Medicine, University Medical Center Groningen, Groningen, The Netherlands

Abstract

Background Phase III studies have demonstrated reduced exacerbation rates with tiotropium Respimat® (tioR) add-on to ICS + LABA in patients with symptomatic asthma (Kerstjens et al. NEJM 2012;367:1198–207). There are currently no reported specific treatments for asthma that work equally well in both TH2-low and TH2-high phenotypes. We explored, in patients with moderate or severe symptomatic asthma, whether TH2 status influenced tioR responses, assessed by time to first exacerbation.

Methods In two 48-week trials (PrimoTinA-asthma®: NCT00776984/NCT00772538), patients on ICS + LABA (≥800 µg budesonide or equivalent) received once-daily tioR 5 µg or placebo Respimat®. In two 24-week trials (MezzoTinA-asthma®: NCT01172808/NCT01172821), patients on ICS (400–800 µg budesonide or equivalent) received once-daily tioR 5 µg or 2.5 µg, twice-daily salmeterol 50 µg via hydrofluoroalkane metered-dose inhaler (active comparator) or placebo (identical devices in a double-dummy protocol). Pre-planned analyses (pooled data) of time to first severe exacerbation and time to first episode of asthma worsening were performed in TH2-low and TH2-high subgroups: total serum immunoglobulin (IgE) ≤ or >430 µg/L (179.2 IU/L); blood eosinophils ≤ or >0.6 × 109/L (600/μL).

Results 912 patients with severe asthma received tioR 5 µg or placebo Respimat®: 205/182 were reported with IgE >430 µg/L and 99/87 with an eosinophil count of >0.6 × 109/L. 2100 patients with moderate asthma received tioR 5 µg or 2.5 µg, salmeterol or placebo: 319/320/319/326 were reported with IgE >430 µg/L and 104/103/111/107 with an eosinophil count of >0.6 × 109/L. Time to first severe exacerbation was longer with tioR versus placebo (Table 1) in patients with severe or moderate asthma, independent of IgE and eosinophils (interaction p values [Cox regression] 0.169 and 0.754, respectively, for PrimoTinA-asthma®; analyses not performed for MezzoTinA-asthma® because of low incidence of severe exacerbations). Time to first asthma worsening was longer with tioR versus placebo (Table 1) in patients with moderate or severe asthma, independent of IgE (interaction p values 0.998 [PrimoTinA-asthma®] and 0.041 [MezzoTinA-asthma®]) and eosinophils (interaction p values 0.251 [PrimoTinA-asthma®] and 0.125 [MezzoTinA-asthma®]).

Abstract P151 Table 1

Risk of severe asthma exacerbation and asthma worsening in PrimoTinA-asthma® and MezzoTinA-asthma®

Conclusion Once-daily tiotropium Respimat® add-on to at least ICS reduced the risk of severe exacerbation and asthma worsening in patients with moderate or severe symptomatic asthma, independent of TH2 phenotype.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.